SC
ANIP icon

Scholtz & Company’s ANI Pharmaceuticals ANIP Stock Holding History

Scholtz & Company’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-39,210
Closed -$1.77M – 40
2015
Q4 		$1.77M Buy
39,210
+11,130
+40% +$479K 1.86% 27
2015
Q3 		$1.11M Buy
+28,080
New +$1.6M 1.19% 36

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $2.66B AUM 26.2% 1-Year Est. Return

Scholtz & Company's ANIP Position: Q1 2016 in Review

Scholtz & Company sold out of ANI Pharmaceuticals (ANIP) in Q1 2016, closing a stake of 39,210 shares — an estimated $1.77M sold.

Scholtz & Company first reported a position in ANIP in Q3 2015 and held it in 2 quarters. The position peaked at $1.77M in Q4 2015. 121 funds tracked by Wall St. Rank hold ANIP as of Q1 2016.

  • Scholtz & Company reported no remaining ANI Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Scholtz & Company sold 39,210 ANI Pharmaceuticals shares in Q1 2016, an estimated $1.77M.
  • Scholtz & Company first reported a position in ANI Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Scholtz & Company's ANI Pharmaceuticals position peaked at $1.77M in Q4 2015.
  • 121 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2016.

Based on Scholtz & Company's 13F filing for Q1 2016, filed 16 May 2016.